Zymeworks Inc. (ZYME)
After hours:
| Previous close | 5.82 |
| Open | 5.73 |
| Bid | 6.02 x 900 |
| Ask | 6.15 x 1200 |
| Day's range | 5.61 - 6.08 |
| 52-week range | 4.56 - 39.41 |
| Volume | |
| Avg. volume | 1,766,998 |
| Market cap | 346.049M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
VANCOUVER, British Columbia & SEATTLE, May 20, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its Board of Directors, after thorough consultation with its financial and legal advisors, unanimously determined that the unsolicited, opportunistic, non-binding proposal from an activist shareholder, All Blue Falcons FZE ("All Blue"), and its affiliates to purchase Zymeworks for $10.50 per s
- PR Newswire
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
All Blue Capital ("AB"), a global investment firm, today announced that Siddhartha Mukherjee, MD, Associate Professor of Medicine in the Division of Hematology/Oncology at Columbia University Medical Center in New York City, recently joined AB as Medical Advisor.
- Business Wire
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
VANCOUVER, British Columbia, May 04, 2022--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
